Business Growth For The Quarter Ended 2020-12-31
As a pre-revenue company, HEPA is currently working through the stages of ideation, discovery and validation. I feel that it is necessary to follow this stock on a day-by-day basis. HEPA reports very significant research and development expenses growth, which investors will appreciate. It means that Hepion Pharmaceuticals Inc is in the process of creating new products. Hence, traders will most likely expect sales in the near future. R&D expenses are equal to $11.997272 million.
Balance Sheet As Of 2020-12-31
HEPA shows $40 million in cash and cash equivalents. In my experience, the company has a good amount of cash to conduct additional R&D and increase its marketing efforts. Moreover, Hepion Pharmaceuticals Inc has positive working capital, which market participants will like. It means that HEPA can cover its short-term liabilities when they come due.
HEPA’s short term debt is less significant than the company’s cash and cash equivalents. In my experience, Hepion Pharmaceuticals Inc may not have to worry about any liquidity risk. Moreover, the price to book value is below 1. 5x, which means that HEPA is undervalued.
Additionally, notice that the cash per share is equal to $4, and the stock price is $1. 91. HEPA’s debt to equity ratio is below 2x. In short, the debt level appears to be under control. Note that Hepion Pharmaceuticals Inc reports cash and cash equivalents of $40 million, and net debt of $-40 million.
Quarterly Results For The Quarter Ended 2020-12-31
HEPA’s R&D expenses were equal to $11. 997272 million, with selling and marketing expenses of $0. 8148803 million. Taking this into account, many traders will most likely have a look at HEPA.
Valuation and Risks
Institutional investors MORGAN STANLEY, HAP Trading, LLC, and AIGH Capital Management LLC are Hepion Pharmaceuticals Inc investors. The company shows a beta of 1. 86571. It is more significant than 1, which means that the stock price can show huge volatility. HEPA’s stock price volatility is larger than that of the market. In short, if you are not a volatility expert don’t trade Hepion Pharmaceuticals Inc.
The following HEPA’s insiders acquired or sold equity recently.HEPA’s traders will most likely study this information:
+In 2021-02-18, director, officer: CEO and Director Foster Robert T acquired equity of HEPA.
+In 2021-02-18, officer: Chief Financial Officer Cavan John T acquired stock of HEPA.
+In 2021-02-16, director Wijngaard Peter acquired equity of HEPA.
Hepion Pharmaceuticals, Inc. engages in the development and commercialization of pleiotropic drug therapy for the treatment of chronic liver disease. The company is headquartered in Edison, New Jersey and currently employs 14 full-time employees.
If you see an error, please contact the editor. We don’t own HEPA’s shares, and this is our opinion. We do not offer a recommendation to buy or sell any stock.